Piaskledin 300 kaps. No. 15

Pharmacological properties

during the researches in vitro and in Vivo in group of patients with an osteoarthrosis which results showed the following main pharmacological properties:

• strengthen collagen synthesis by articulate chondrocytes and reduce synthesis of IL-1 (interleukins-1) chondrocytes;
• raise PAI-1 expression (inhibitor of plasminogen activator, the fraction inhibiting plasminogen activator that causes injuries of a joint in an osteoarthrosis);
• raise an expression of a transforming factor of growth β (TGF-β) in chondrocytes which was recognized later showing anabolic properties of rather cartilaginous tissue.

chance to consider that medicament Piaskledin 300 stimulates TGF-β that leads to restoration of an extracellular matriksny component in articulate cartilaginous tissue.

At assessment of action of Piaskledin 300, namely on values of 3 chosen indexes (inflammations of gums, bleeding of gums, bleedings when sounding), noted reduction of expressiveness of inflammation of gums.

noted considerable reduction of number of aggravations of inflammation of gums at treatment of patients by Piaskledin 300.

Indication

In rheumatology: symptomatic treatment of an osteoarthrosis of knee and hip joints.

In stomatology: auxiliary treatment of periodontitis.

Use

is Applied the adult inside.

Accept 1 capsule of 1 times a day at meal time, washing down with one glass of water. The capsule should not be chewed.

If missed administration of drug, next day it is necessary to accept a usual dose, it is not necessary to double a dose. Duration of a course of treatment 300 is defined by Piaskledin according to the recommendations of the doctor.

Contraindication

Hypersensitivity to medicament components.

Side effects

Criteria for evaluation of frequency of development of side reactions: very often (≥1/10), it is frequent (≥1/100, 1/10); infrequently (≥1/1000, 1/100), it is rare (≥1/10,000, 1/1000), is very rare (1/10,000), frequency is unknown (it is impossible to determine by the available data).

from digestive system: very seldom — an eructation with zhiropodobny smack which can be avoided, accepting the capsule at meal time, diarrhea and epigastric pain.

from a liver and biliary tract: very seldom — increase in transaminases, SF, bilirubin and a gammaglutamiltranspeptidaza.

from the immune system: very seldom — reactions of hypersensitivity.

in case of side effects or deterioration in symptoms of a disease should see a doctor.

Special instructions

Medicine contains soy oil therefore in an allergy to products from soy or peanut it is not necessary to use drug.

Piaskledin 300 belongs to the new class of SYSADOA medicines (symptomatic slow-acting means for treatment of an osteoarthrosis) which main property is their delayed action. For this reason in an initiation of treatment medicament Piaskledin 300 it is possible to recommend purpose of NPVP and/or analgetics which dose should be reduced gradually according to increase in efficiency of Piaskledin 300.

Use during pregnancy and feeding by a breast. Drug use studies with participation of pregnant women were not conducted therefore do not recommend to use medicament during pregnancy.

data on use of medicament during feeding by a breast therefore it is necessary to refrain from use of medicament during this period.

Children. Drug should not be used at children (aged up to 18 years) due to the lack of researches of efficiency and safety of this medicament at patients of this age category.

Ability to influence speed of response at control of vehicles or work with other mechanisms. Piaskledin 300 has no known impact on ability to control of vehicles or work with other mechanisms.

do not have

Interaction

Should consult with the doctor before simultaneous use of several medicines to prevent interaction between them.

Overdose

.

At accidental reception of the dose exceeding daily should see a doctor.

Storage conditions

At a temperature not above 25 °C, out of children's reach.